NY-AQARA
Aqara, a leading provider of smart home solutions, is thrilled to announce the expansion of its smart lighting product line with the introduction of the Ceiling Light T1M. This smart light fixture seamlessly blends radiant white lights with a colorful gradient ring for everyday and atmospheric illumination. The Ceiling Light T1M is available on Aqara’s Amazon brand stores in North America (US, Canada) and Europe (France, Germany, Italy, Poland, Spain, UK) as well as through select Aqara retailers worldwide*.
Designed for rooms ranging from 5 to 20 square meters (approximately 54 to 215 square feet), this ceiling light offers a versatile lighting solution. With a spectrum ranging from warm-to-cool whites (2700-6500K) to an impressive 16 million colors, users can effortlessly create the perfect ambiance for any mood or occasion. Moreover, its independently addressable RGB ring enables seamless integration into holistic smart home experiences, allowing users to visually receive notifications or alerts regarding their home’s status changes, such as when someone rings the Aqara doorbell or triggers an armed security system. For hearing-impaired individuals, the T1M Ceiling Light can be paired with smart security alarm systems to add customized visual alerts, further enhancing the safety and convenience for users.
Similar to other Aqara Zigbee devices, the Ceiling Light T1M supports Matter and other major platforms, such as Apple Home (including Adaptive Lighting for HomeKit users), Amazon Alexa, and Google Home, via a compatible Aqara hub*. The wide compatibility positions it as a future-proof addition to any space. The ceiling light features low idle power consumption thanks to the energy-efficient Zigbee protocol, while also serving as a repeater of the Zigbee network, enhancing network range and responsiveness. Zigbee also ensures local automation to remain functional even when the ceiling light is disconnected from the internet. Engineered for excellence, the T1M features a Color Rendering Index (Ra) of 90 for true-to-life hues and has undergone rigorous testing to ensure a lifespan of 50,000 hours for longevity.
Expanding upon the success of the LED Strip T1, the Ceiling Light T1M represents the latest addition to Aqara's smart light portfolio, furthering the Company's commitment to creating the ultimate smart home experience. With smart light being an integral part of a truly smart home, the T1M harmonizes with other Aqara devices to elevate everyday living. For example, the T1M can be paired with presence or motion sensors for automated illumination, which helps cut energy waste. Moreover, by coupling it with an Aqara light switch, which features Wireless Switch mode, users can enjoy the familiarity of traditional light control while preserving the sophistication of the Ceiling Light's smart functionality.
For more information on the Ceiling Light T1M, please visit our website.
* Product availability may vary among different retail channels and could be updated on an ongoing basis. It’s recommended to check with the regional retailer(s) for real-time availability.
** The Matter compatibility of the Ceiling Light T1M requires a Matter-compatible Aqara hub (e.g., Hub M2, Hub M1S/M1S Gen 2, Hub E1, Camera Hub G3) and may be in Beta by the time of its launch.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229437381/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom